©kirkikis/AdobeStock

The 2025 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting (ACSM), held in Minneapolis, MN, has officially come and gone, with hundreds of sessions, abstracts, and posters presented on the latest data, recommendations, and calls to action.

Patient Care® Online covered several sessions, poster sessions, and oral abstracts from the meeting, and interviewed multiple presenting authors and experts across a variety of conditions.

Below, we recap our complete coverage from the meeting, with direct links to our full articles, video interviews, and Q+A discussions with presenting authors.

Articles

Primary Care Falls Short in Managing Adolescent Heavy Menstrual Bleeding, Researchers Warn

Researchers reviewed records of 345 adolescents aged 9 to 16 years who sought initial evaluation for HMB from a primary health care professional (PCP) between January 2017 and June 2019. Patients were identified using ICD-10 codes, with chart review confirmation. The study evaluated provider actions during initial visits, including discussion of hormonal contraceptive prescriptions and gynecologic referrals.

Results showed that while 74.4% of the adolescents engaged in discussions about hormonal contraception, only 46.9% ultimately received prescriptions. The authors stressed that, notably, 23.7% of these discussions were initiated by patients or their families. In addition, only 10.7% of adolescents were referred to a gynecologist.

Click here for the full article.

ACOG Issues Consensus Guidance to Improve Pain Control During In-Office Gynecologic Procedures

ACOG released long-awaited guidance on pain management for in-office uterine and cervical procedures on May 15, 2025. The clinical consensus document, Pain Management for In-Office Uterine and Cervical Procedures, covers common interventions such as intrauterine device (IUD) insertion, endometrial biopsy, hysteroscopy, intrauterine imaging, and cervical biopsy. ACOG recommends that obstetrician-gynecologists routinely discuss local anesthesia — including topical lidocaine spray, lidocaine–prilocaine cream, or a paracervical block — for IUD placement and tailor similar strategies, along with nonsteroidal anti-inflammatory drugs or misoprostol, to other office procedures.

Click here for the full article.

Elinzanetant Demonstrates Clinically Meaningful Reductions in Menopausal Vasomotor Symptoms, Meta-analysis Shows

Investigators performed a systematic review and meta-analysis of 3 randomized controlled trials encompassing 995 participants, with 551 women receiving elinzanetant and 444 receiving placebo. The pooled data revealed that elinzanetant reduced daily hot-flash frequency compared with placebo and lowered VMS intensity scores. Health-related quality-of-life benefits paralleled symptom relief. Scores on the Menopause-Specific Quality of Life Questionnaire declined, and sleep-disturbance scores on the PROMIS Sleep Disturbance Short Form 8b improved versus placebo. Importantly, the incidence of treatment-emergent adverse events did not differ significantly between elinzanetant and placebo groups.

Click here for the full article.

Expert Interviews

From Screening to Support: How PCPs Can Tackle PPD

Joy Baker, MD, leaves primary care clinicians with two key takeaways from her presentation on postpartum depression (PPD) at ACOG 2025: you have the power to change outcomes, and you don’t have to do it alone.

Click here for the full interview.

Provider Gaps in Postpartum Depression Screening and Management Highlighted in New Study

Despite widespread awareness of PPD screening guidelines, significant gaps persist in clinical practice, according to research presented by Laxmi Gannu, MS, senior manager, real world evidence, at Sage Therapeutics. In this interview, Gannu reviews results from a national provider survey assessing adherence to screening protocols, follow-up care, and provider training. The findings reveal inconsistencies in protocol implementation, surprising misconceptions among physicians, and distinct differences in practice patterns between provider types.

Click here for the full interview.

Nanette Santoro, MD, Highlights Findings on Fezolinetant From Pooled Analysis of Phase 3 Skylight Development Program Trials

In results of a new pooled analysis of pivotal phase 3 clinical trials, presented by lead author Nanette F. Santoro, MD, fezolinetant was associated with small but consistent reductions in waist circumference and body roundness index (BRI), the latter of which estimates visceral fat. In an interview with Patient Care©, Dr Santoro explained that as the 2 measures of adiposity diminished over the 52-week study period, participants' overall weight and body mass index remained relatively stable, a positive trend in women going through menopause.

Click here for the full interview.

PPD Screening, Medicaid Coverage, and Access to Care: A Q&A with Elizabeth Mollard, PhD

Patient Care editors spoke with Elizabeth Mollard, PhD, whose recent research explored how state-level Medicaid policies affect rates of PPD diagnosis. In our interview Mollard highlighted the importance of universal screening, the challenges faced by vulnerable populations, and the implications of Medicaid expansion—or lack thereof—on maternal mental health care.

Click here for the full interview.

For other highlights and exclusive expert interviews, check out our full meeting coverage of the 2025 ACOG ACSM here.